Longitudinal DSC-MRI for distinguishing tumor recurrence from pseudoprogression in patients with a high-grade glioma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 40, Issue 3, 2017, Pages 228-234

  Boxerman, Jerrold L ^a,b   Ellingson, Benjamin M ^c,d   Jeyapalan, Suriya ^a,b   Elinzano, Heinrich ^a,b   Harris, Robert J ^c   Rogg, Jeffrey M ^a,b   Pope, Whitney B ^c   Safran, Howard ^a,b  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Engineering IV   (United States)

Author keywords

chemoradiation; dynamic susceptibility contrast MRI; progressive disease; pseudoprogression; relative cerebral blood volume

Indexed keywords

GADOBUTROL; GADOLINIUM PENTETATE MEGLUMINE; PACLITAXEL POLIGLUMEX; TEMOZOLOMIDE; CONTRAST MEDIUM;

ADULT; AGED; ARTICLE; BRAIN BIOPSY; BRAIN BLOOD VOLUME; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING; DYNAMIC SUSCEPTIBILITY CONTRAST PERFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FOLLOW UP; GLIOMA; HUMAN; HUMAN TISSUE; MALE; MULTICENTER STUDY (TOPIC); NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE SCANNER; PERFUSION WEIGHTED IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); RECURRENT DISEASE; SINGLE DRUG DOSE; BIOPSY; BRAIN; BRAIN NEOPLASMS; CANCER GRADING; DIAGNOSTIC IMAGING; DISEASE COURSE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; TIME FACTOR; TUMOR RECURRENCE;

ADULT; AGED; BIOPSY; BRAIN; BRAIN NEOPLASMS; CEREBRAL BLOOD VOLUME; CONTRAST MEDIA; DISEASE PROGRESSION; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; TIME FACTORS;

EID: 84914126663     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000156     Document Type: Article

References (29)

1. Stupp R, Mason WP, Van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996
2. Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008; 9: 453-461
3. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J ClinOncol. 2008; 26: 2192-2197
4. Shonka NA, Theeler B, Cahill D, et al. Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. J Neurooncol. 2013; 113: 305-311
5. Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, et al. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. Am J Neuroradiol. 2011; 32: 1978-1985
6. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28: 1963-1972
7. Young RJ, Gupta A, Shah AD, et al. Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology. 2011; 76: 1918-1924
8. Fatterpekar GM, Galheigo D, Narayana A, et al. Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum-use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI. Am J Roentgenol. 2012; 198: 19-26
9. Villringer A, Rosen BR, Belliveau JW, et al. Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects. Magn Reson Med. 1988; 6: 164-174
10. Rosen BR, Belliveau JW, Vevea JM, et al. Perfusion imaging with NMR contrast agents. Magn Reson Med. 1990; 14: 249-265
11. Mangla R, Singh G, Ziegelitz D, et al. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology. 2010; 256: 575-584
12. Young RJ, Gupta A, Shah AD, et al. MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clin Imaging. 2013; 37: 41-49
13. Tsien C, Galban CJ, Chenevert TL, et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol. 2010; 28: 2293-2299
14. Kong DS, Kim ST, Kim EH, et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. Am J Neuroradiol. 2011; 32: 382-387
15. Hu LS, Eschbacher JM, Heiserman JE, et al. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro-oncol. 2012; 14: 919-930
16. Sugahara T, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrastenhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol. 2000; 21: 901-909
17. Barajas RF Jr, Chang JS, Segal MR, et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibilityweighted contrast-enhanced perfusion MR imaging. Radiology. 2009; 253: 486-496
18. Jeyapalan S, Boxerman J, Donahue J, et al. Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study. Am J Clin Oncol. 2014; 37: 444-449
19. Singer JW. Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. J Control Release. 2005; 109: 120-126
20. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. Am J Neuroradiol. 2006; 27: 859-867
21. Hu LS, Baxter LC, Pinnaduwage DS, et al. Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. Am J Neuroradiol. 2010; 31: 40-48
22. Ellingson BM, Cloughesy TF, Lai A, et al. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro-oncol. 2011; 13: 401-409
23. Gerstner ER, McNamara MB, Norden AD, et al. Effect of adding temozolomide to radiation therapy on the incidence of pseudoprogression. J Neurooncol. 2009; 94: 97-101
24. Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol. 2009; 92: 317-335
25. Sanghera P, Rampling R, Haylock B, et al. The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas. Clin Oncol (R Coll Radiol). 2012; 24: 216-227
26. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between imageguided tissue histopathology and localized dynamic susceptibilityweighted contrast-enhanced perfusion MR imaging measurements. Am J Neuroradiol. 2009; 30: 552-558
27. Gasparetto EL, Pawlak MA, Patel SH, et al. Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. Radiology. 2009; 250: 887-896
28. Gahramanov S, Raslan AM, Muldoon LL, et al. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys. 2011; 79: 514-523
29. Di Chiro G, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. Am J Roentgenol. 1988; 150: 189-197